Structure Therapeutics 'encouraged' by 5.4% weight loss with its oral GLP-1, plans for more studies

Katherine Lewin

News Reporter

Structure Therapeutics is throwing its oral GLP-1 into the weight loss ring with promising — albeit early and small — data from a Phase Ib trial investigating …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Structure Therapeutics 'encouraged' by 5.4% weight loss with its oral GLP-1, plans for more studies

Katherine Lewin

News Reporter

Sign up to read this article for free.

Sr. Manager/Associate Director, Document Control

Viridian Therapeutics

Waltham, MA, USA

Sanofi's BTK inhibitor again slows MS progression, but liver enzymes continue to be tricky

Lexicon's president to step down as decision date looms; Sarepta welcomes Lilly, GSK vet to board

Gilead's Kite uncouples from Fosun in China as Yescarta faces coverage obstacles

Aligos’ trial for oral MASH treatment succeeds, but placebo group shows odd trend

FDA inspectors discover trucks carrying torn-up records leaving Indian generics factory

Breaking down silos with a new quantitative approach to drug development

Struc­ture Ther­a­peu­tics 'en­cour­aged' by 5.4% weight loss with its oral GLP-1, plans for more stud­ies

News Reporter

Sign up to read this article for free.

Viridian Therapeutics

Waltham, MA, USA

Structure Therapeutics 'encouraged' by 5.4% weight loss with its oral GLP-1, plans for more studies